Deciphera to Acquire UroGen Pharma for $755M

Ticker: URGN · Form: 8-K · Filed: 2024-06-13T00:00:00.000Z

Sentiment: bullish

Topics: acquisition, merger, healthcare

TL;DR

Deciphera is buying UroGen for $755M ($19.50/share) in cash, deal expected Q3 2024.

AI Summary

UroGen Pharma Ltd. announced on June 13, 2024, that it has entered into a definitive agreement to be acquired by Deciphera Pharmaceuticals, LLC. The transaction is valued at approximately $755 million, with Deciphera acquiring all outstanding shares of UroGen for $19.50 per share in cash. This acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions.

Why It Matters

This acquisition significantly consolidates the uro-oncology space, potentially impacting the competitive landscape and future treatment options for patients.

Risk Assessment

Risk Level: medium — The deal is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the acquisition.

Key Numbers

Key Players & Entities

FAQ

What is the total value of the acquisition agreement between UroGen Pharma and Deciphera Pharmaceuticals?

The definitive agreement values the transaction at approximately $755 million.

What is the price per share being offered to UroGen Pharma shareholders?

Deciphera Pharmaceuticals is acquiring all outstanding shares of UroGen for $19.50 per share in cash.

When is the acquisition of UroGen Pharma by Deciphera Pharmaceuticals expected to close?

The transaction is expected to close in the third quarter of 2024.

What are the primary conditions for the closing of the acquisition?

The acquisition is subject to customary closing conditions, which include regulatory approvals.

What is the filing date of this Form 8-K report?

This Form 8-K report was filed on June 13, 2024.

Filing Stats: 1,795 words · 7 min read · ~6 pages · Grade level 11.7 · Accepted 2024-06-13 10:51:32

Key Financial Figures

Filing Documents

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, the Company can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as "could," "estimate," "expect," "intend," "may," "plan," "potentially," or "will" or similar expressions and the negatives of those terms. These statements include, but are not limited to, statements regarding the potential for the Company to transform bladder cancer treatment; the potential of JELMYTO to change the treatment paradigm in low-grade upper tract urothelial cancer ("LG-UTUC"); the potential of UGN-102 to transform the treatment paradigm in LG-IR-NMIBC; the potential of UGN-301 to expand to Immuno-Oncology for high-grade non-muscle invasive bladder cancer ("HG-NMIBC"); the estimated patient population in bladder cancer and estimated addressable patient population for UGN-102 in LG-IR-NMIBC and UGN-301 in HG-NMIBC; the estimated total addressable market opportunity for UGN-102 in LG-IR-NMIBC; the expected price range per dose for UGN-102; the potential for UGN-102 to become the first FDA-approved medicine for LG-IR-NMIBC; the opportunity and potential benefits of UGN-102 for LG-IR-NMIBC and potential advantages over TURBT; the potential NDA completion and review timeline for UGN-102, including the FDA's potential acceptance thereof and approval of UGN-102 and the timing thereof; the potential of the Company's proprietary RTGel technology platform to improve therapeutic profiles of existing drugs; and t

Financial Statements and Exhibits. (d) Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Company Presentation, dated June 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: June 13, 2024 UROGEN PHARMA LTD. By: /s/ Don Kim Don Kim Chief Financial Officer

View on Read The Filing